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Conclusions: Patients with a history of a serious infection after vaccination had
lower antibody levels compared to those without such infections. Cut-off levels of
post-vaccination antibody titers associated with protection for serious infections
corresponded to those of ≥1 mg/L being generally considered as protective at
our laboratory. Frequency of positive antibody response to vaccination did not
differ between patients with and without serious infections.
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Background: There is a need to enable comparable spondyloarthropathy (SpA)
prevalence estimates in Europe, which was made possible by the unique European
EULAR project methodology
Objectives: to estimate the SpA prevalence in Serbia, as part of the EULAR
study
Methods: In a detection phase, a previously translated and validated telephone
Questionnaire comprising of signs, symptoms and self-reported diagnosis (1)
was used by 30 lay interviewers on a representative sample of 6213 randomly
selected telephone numbers (every 100-th), from urban Serbian population:
Belgrade (north) and Cacak, Uzice and Krusevac (south). Suspected cases have
received a second call by a rheumatologist. In a confirmation phase, for patients
with self-reported diagnosis and positive symptoms patient’s rheumatologist was
contacted to confirm diagnosis; a complete rheumatologist examination was
arranged for those with positive symptoms only. Prevalence estimates were
standardised for age and sex with relation to Serbian population (census 2002).
Results: The response rate was 63,6% (3950 respondents). Second call
was received by 571 people, among whom 16 SpA cases were confirmed
(11 diagnosed previously and 5 newly-diagnosed during the rheumatology
examination). The Serbian standardized SpA prevalence was 0,32% (95%
confidence interval-CI: 0,14-0,50), it was 0,34% (95% CI 0,04-0,64) for men and
0,31% (95% CI: 0,09-0,53) for women. The prevalence for ankylosing spondylitis
was 0,08% (95% CI 0,03-0,13), for psoriatic arthritis 0,09% (95% CI 0,03-0,15),
for reactive arthritis (morbus Reiter) 0,10% (95% CI 0,04-0,16), for enteropathic
arthritis (associated with inflammatory bowel diseases) 0,03% (95% CI 0,00-0,06)
and for undifferentiated spondyloarthropathy 0,02% (95% CI 0,00-0,05).
Conclusions: Compared to prevalence studies using the same methodology and
design, SpA prevalence estimates in Serbia are close to France (2), but lower
than those reported from Lithuania (3).
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Background: Patients with rheumatic diseases commonly experience fatigue and
this fatigue has a substantial impact on patients’ self-care activities and overall
quality of life. Fatigue levels and the expression of fatigue may be modified by
cultural differences as has been demonstrated for pain (1). However qualitative
studies of fatigue in non-European cultures are lacking.
Objectives: The objective of this qualitative study was to increase the under-
standing of the fatigue experience and characteristics among Egyptian patients
with rheumatic diseases: rheumatoid arthritis (RA), fibromyalgia (FM) and axial
spondyloarthritis (AxSpA).
Prospective monocentric qualitative study based on conventional qualitative
content analysis, inductive reasoning, grounded theory. Consecutive patients with
definite disease (either RA, FM or AxSpA) were invited to participate in 30-min
interviews. Patients were asked about fatigue, its patterns, consequences and
self-management. Interviews were recorded by audiotape, transcribed verbatim
and all phrases were systematically coded until overarching themes appeared.
Methods: Prospective monocentric qualitative study based on conventional
qualitative content analysis, inductive reasoning, grounded theory. Consecutive
patients with definite disease (either RA, FM or AxSpA) were invited to
participate in 30-min interviews. Patients were asked about fatigue, its patterns,
consequences and self-management. Interviews were recorded by audiotape,
transcribed verbatim and all phrases were systematically coded until overarching
themes appeared.
Results: Of the 60 patients interviewed, 20 patients had each disease (RA, FM
and AxSpA). Patients were mainly male (N=40, 66%), had 3 to 7 years (mean)
of disease duration and had moderate disease activity. Fatigue was high with
median fatigue visual analog scales (0-10) of 50 in RA, 70 in FM and 40 in
AxSpA. Concept of fatigue: Fatigue was a difficult concept for patients; when
clarified, RA and FM patients described fatigue as the need to rest more whereas
AxSpA patients described fatigue as a freezing of the body. Consequences of
fatigue: In all diseases, the participants stated that fatigue influenced and affected
physical activity and work, whereas fatigue had a major impact on social and
leisure activities only for RA and FM patients (AxSpA patients not stating such
a limitation). Fatigue affected sexual activity markedly in all disease groups and
this was a major concern of most of the participants. Self-management of fatigue:
Patients felt their fatigue was ignored from medical staff and from families alike;
however RA patients expressed getting more help from their family.
Conclusions: This study gives insights into fatigue in rheumatic diseases in an
Arabic and Muslim culture. We found that the characteristics of fatigue and its
consequences had some differences from previously reported European studies;
these differences may be attributed mainly to cultural reasons.
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Background: Studies show patients with knee osteoarthritis (OA) on waiting list for
total knee replacement (TKR) underused conservative treatment, did not adhere
to clinical guidelines on knee OA management, and potentially had earlier surgery
and a higher risk of revisions. Therapeutic education and functional readaptation
(TEFR) plus conventional therapy in waiting list patients improved function and ad-
herence. TKR patients are often obese, negatively influencing TKR results, many
patients are dissatisfied after TKR, and around 14% of TKR are inappropriate.
Objectives: To compare whether TEFR plus conventional therapy improves
health outcomes in obese patients (body mass index [BMI ≥35]) with knee OA
and a control group receiving conventional therapy only at entry to a TKR waiting
list and after 12 months.
Methods: Case-control study with 18 months follow-up. TERF patients received
conventional medical and surgical treatment plus TEFR (n=59). TERF combined
individualized and group visits (4 months before TKR) based on cognitive learning
theories, social change approaches and active teaching strategies. Controls were
matched for age, sex, BMI and total WOMAC score (n=59). Sociodemographic,
clinical and intra- and postoperative surgical data were collected. The health status
was measured using the disease-specific WOMAC questionnaire. Evaluations:
baseline, 12 months post TKR, and 4 months post baseline in the TEFR group.
Results: TEFR group: 56 female, mean age 68.8 (SD 7.8) years, BMI 40.1
(SD 3.8) WOMAC total index 60.5 (17.2). At 4 months there were significant
improvements in all WOMAC dimensions (p<0.001). At 4 months, 10 patients
refused surgery due to improvement. At 12 months after TKR (n=49) there
was a significant improvement compared with scores at 4 months (p<0.001)
and baseline with a mean reduction of 34.95 (95%CI 29.8–40.1) points in total
WOMAC score. Control group: 56 female, mean age 70.2 (SD 6.6) years, BMI
40.2 (SD 3.6) and total WOMAC score 63.3 (SD 17.3). At 12 months, there was
a significant improvement in all dimensions (p<0.001) with a reduction in total
WOMAC score of 32.7 (95%CI 26.5-38.8). Between-group comparison showed no
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significant differences at baseline. 12 months after TKR, no significant differences
were found except for the WOMAC function dimension (mean score 19.5 (SD
10.4) in the TEFR group and 30.98 (SD20.5) in controls (p<0.001). Patients
who refused TKR had no significant differences at baseline but were younger
and had a better health status (mean age 65.4 (SD 9.6) years, BMI 40.9 (SD
3.3) and WOMAC score 54.5 (18.7). After 4 months of TEFR they showed mean
improvements in all WOMAC dimensions of >16 points, which was maintained
until study completion.
Conclusions: Patients receiving TEFR plus conventional therapy had better
health outcomes due to improvements in function showing TEFR to be effective.
In 10 who rejected TKR, the health status improved, suggesting the utility of
specific programmes to treat patients before inclusion on waiting lists.
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Background: Tumour necrosis factor inhibitors (TNFi’s) such as etanercept (ETN),
adalimumab (ADA) and infliximab (IFX) have led to dramatic improvements in the
treatment of rheumatoid arthritis (RA), but their impact on medical expenditures
remains a concern. It is therefore important to aim for sustained clinical benefits
through persistent treatment whilst minimizing the impact of the drug cost on
medical expenditures based on initiating the most cost-effective RA treatment.
Objectives: The aim of this study is to evaluate retention rates across three
commonly used TNFi’s and compare associated cumulative direct biologics and
medical costs using a nationwide Japanese claims database containing about
two million subscribers from the health insurance society provided by the Japan
Medical Data Center Co., Ltd.
Methods: Subjects of this study were patients with rheumatoid arthritis (ICD10
code: M058, M059, M060, M068, M069) prescribed ETN, IFX or ADA as the first
biologics between January 2005 and March 2013. Annual average costs of the
initial biologics per patient were calculated between 2005 and 2012. Next, the
retention rates of ETN, IFX and ADA were examined using Kaplan-Meier survival
analysis. Lastly, the cumulative biologics cost including second (or subsequent)
biologics (tocilizumab, abatacept, golimumab, certolizumab and three TNFi’s) as
well as the total medical costs were compared in the year following the initial
prescription of ETN, IFX or ADA (The approved dose in Japan for ETN: 10 to 25
mg twice weekly or 25 to 50 mg per week, IFX: 3 to 10mg/kg every 4 to 8 weeks,
ADA: 40 to 80mg every 2 weeks).
Results: 524 RA patients initiating selected biologic therapy were identified for
this analysis. 238, 217 and 69 patients were prescribed ETN, IFX, ADA as the
first biologic, respectively. The annual cost for ETN per patient was about $10,000
in 2007 and $7,200 in 2012. The annual cost for IFX per patient was about
$13,000 in 2007, but after approval of dose escalation in 2009, it was $16,000
in 2012. The retention rate of each TNFi at 36 months was 51.4%, 42.0% and
24.2% for ETN, IFX and ADA, respectively (ETN vs. IFX, p=0.053; ETN vs.ADA,
p=0.004, Log-rank test) (Fig.1). The average cumulative annual cost of biologics
for patients initiated with ETN, IFX and ADA as the first biologics treatment was
about $12,000, $18,000 and $16,000, respectively (ETNvs IFX, p<0.001; ETN
vs. ADA, p<0.001, IFX vs. ADA, p=0.751, Steel-Dwass test) (Fig.2). The average
total annual medical cost with ETN, IFX and ADA as the first biologics treatment
were $19,000, $26,000 and $23,000, respectively (ETN vs IFX, p<0.001, ETN
vs. ADA, p<0.001, IFX vs. ADA, p=0.826, Steel-Dwass test).
Conclusions: The retention rate of ETN as the first biologics treatment was the
highest among three TNFi’s while cumulative annual cost of biologics and total
medical cost following the initial treatment of patients with ETN was significantly
lower than comparators. Therefore, ETN may be considered a more cost-effective
option to other TNFi’s although further research comparing clinical outcomes is
warranted.
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Background: Patient reported outcome (PRO) tools are uniquely informative
for management of systemic lupus erythematosus (SLE) patients. Fatigue is an
important component of PRO. Patients with SLE experience significant fatigue
and its association with standard disease activity measures in SLE is inconsistent.
Objectives: To compare patient self-reported fatigue using two different PRO tools
– Multi-dimensional health assessment questionnaire (MDHAQ) and LupusPRO
(a disease-specific PRO for SLE) in patients with and without a current SLE flare
as determined by the SELENA flare Index (SFI).
Methods: 121 patients meeting ACR criteria for SLE completed MDHAQ and
LupusPRO during a routine clinic visit. Disease activity assessments were made
by SELENA-SLEDAI Physician global assessment (SLEDAI-PGA), total SLEDAI
and SFI. Fatigue on MDHAQ (MDHAQ-F) was marked on a visual analogue scale
of 0-10. Fatigue from LupusPRO was calculated on a scale of 0-100 using 5
Pain-Vitality domain questions on pain and fatigue. LupusPRO Pain-Vitality scores
were coded to reflect greater fatigue with an increase in scores. Independent
sample t-test was used to compare fatigue by SFI status. Data were then stratified
by physician diagnosis of fibromyalgia (FM) (yes/no). Spearman rho correlation
was used. A p value of ≤0.05 was considered statistically significant on two tailed
tests.
Results: Mean (SD) age, SLEDAI-PGA and total SELENA-SLEDAI scores were
43.2 (13.3) yrs., 0.6 (0.6) and 4.1 (4.7). 95% of the patients were female
and 52% were African-American. Mean (SD) MDHAQ-F was 4.5 (3.4) and on
LupusPRO Pain-Vitality was 40.0 (29.3). MDHAQ-F and LupusPRO Pain-Vitality
were strongly correlated (rho 0.79 (P<0.001)). Twenty one percent had a current
SFI flare. Nearly ¼ of SLE patients had a diagnosis of FM. Mean (SD) MDHAQ-F
were 3.9 (3.3) and 6.2 (3.0) among patients without and with SFI flare (p=0.003)
(Table 1). Mean (SD) LupusPRO Pain-Vitality were 35.1 (28.6) and 53.8 (25.8)
(p=0.005) in patients without and with SFI flare. Patients who did not have FM
had mean (SD) MDHAQ-F scores without and with SFI flare of 2.7 (2.7) and 6.2
(2.8) (p≤0.001) and mean (SD) LupusPRO Pain-Vitality scores without and with
SFI flare of24.0 (22.9) and 51.1 (25.4), (p<0.001). In these patients without FM,
MDHAQ-F and LupusPRO Pain-Vitality were correlated significantly with SLEDAI
PGA and Total SLEDAI (Table). In patients with FM, MDHAQ-F and LupusPRO
Pain-Vitality scores did not differ significantly by SFI status and no significant
correlation with SLEDAI-PGA or Total SLEDAI was seen (Table).
Conclusions: Patient self-reported fatigue scores are directly related to flares,
and should be explored as a possible surrogate marker of SLE flares in patients
